Premenstrual Syndrome Treatment Market by Drug Type (Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-06
- Report ID: 1381
- Pages: 241
-
Format:
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026.
Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability. Lifestyle changes are anticipated to help relieve PMS symptoms. However, based on the severity of symptoms, different types of drugs such as analgesics, antidepressants, and diuretics are used.
The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth.
The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type market is classified as prescription and OTC. According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of major four geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
Analgesics
Antidepressants
Oral Contraceptives & Ovarian Suppression Agents
Others
Type
Prescription
OTC
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
ABBVIE INC.
AstraZeneca plc.
BASF Corporation
Bayer AG
Dr. Reddys Laboratories Ltd
Eli Lilly And Company
GlaxoSmithKline Plc
H. Lundbeck A/S
Pfizer Inc
Shionogi Inc
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Teva Pharmaceutical Industries Ltd.
Allergan PLC
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Key Findings
2.2.1. Top Investment Pockets
2.2.2. Top Player Positioning, 2018
2.3. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Forces Shaping Premenstrual Syndrome Treatment Industry/Market
3.2.1. Moderate Power of Suppliers
3.2.2. Moderate Threat of New Entrants
3.2.3. Low Threat of Substitution
3.2.4. Moderate Competitive Rivalry
3.2.5. Moderate Bargaining Power of Buyers
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Increase In Prevalence of Pms
3.3.1.2. Growth In Awareness For Pms Therapeutics
3.3.1.3. Surge In Healthcare Expenditure Worldwide
3.3.2. Restraint
3.3.2.1. Poor Demand In Under Developed Countries
3.3.3. Opportunities
3.3.3.1. Growth Opportunities In Emerging Markets
3.3.3.2. Higher Number of Unmet Needs For Treatment of Pms
3.3.4. Impact Analysis
Chapter 4: Premenstrual Syndrome Treatment Market, By Drug Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Analgesics
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Antidepressants
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Oral Contraceptives & Ovarian Suppression Agents
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Others
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
Chapter 5: Premenstrual Syndrome Treatment Market, By Type.
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Prescription
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Otc
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
Chapter 6: Premenstrual Syndrome Treatment Market, By Distribution Channel
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospitals Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Drug Stores & Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Analysis, By Country
6.4. Online Pharmacies
6.4.1. Market Size And Forecast
6.4.2. Market Analysis, By Country
Chapter 7: Premenstrual Syndrome Treatment Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Premenstrual Syndrome Treatment Market, By Drug Type
7.2.2.1.2. U.S. Premenstrual Syndrome Treatment Market, By Type
7.2.2.1.3. U.S. Premenstrual Syndrome Treatment Market, By Distribution Channel
7.2.2.2. Canada
7.2.2.2.1. Canada Premenstrual Syndrome Treatment Market, By Drug Type
7.2.2.2.2. Canada Premenstrual Syndrome Treatment Market, By Type
7.2.2.2.3. Canada Premenstrual Syndrome Treatment Market, By Distribution Channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico Premenstrual Syndrome Treatment Market, By Drug Type
7.2.2.3.2. Mexico Premenstrual Syndrome Treatment Market, By Type
7.2.2.3.3. Mexico Premenstrual Syndrome Treatment Market, By Distribution Channel
7.2.3. North America Market Size And Forecast, By Drug Type
7.2.4. North America Premenstrual Syndrome Treatment Market, By Type
7.2.5. North America Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.1.2. Germany Premenstrual Syndrome Treatment Market, By Type
7.3.2.1.3. Germany Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.2. France
7.3.2.2.1. France Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.2.2. France Premenstrual Syndrome Treatment Market, By Type
7.3.2.2.3. France Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.3. Uk
7.3.2.3.1. Uk Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.3.2. Uk Premenstrual Syndrome Treatment Market, By Type
7.3.2.3.3. Uk Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.4. Italy
7.3.2.4.1. Italy Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.4.2. Italy Premenstrual Syndrome Treatment Market, By Type
7.3.2.4.3. Italy Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.5. Spain
7.3.2.5.1. Spain Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.5.2. Spain Premenstrual Syndrome Treatment Market, By Type
7.3.2.5.3. Spain Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.6.2. Rest of Europe Premenstrual Syndrome Treatment Market, By Type
7.3.2.6.3. Rest of Europe Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.3. Europe Market Size And Forecast, By Drug Type
7.3.4. Europe Premenstrual Syndrome Treatment Market, By Type
7.3.5. Europe Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.1.2. Japan Premenstrual Syndrome Treatment Market, By Type
7.4.2.1.3. Japan Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.2. China
7.4.2.2.1. China Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.2.2. China Premenstrual Syndrome Treatment Market, By Type
7.4.2.2.3. China Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.3. Australia
7.4.2.3.1. Australia Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.3.2. Australia Premenstrual Syndrome Treatment Market, By Type
7.4.2.3.3. Australia Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.4. India
7.4.2.4.1. India Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.4.2. India Premenstrual Syndrome Treatment Market, By Type
7.4.2.4.3. India Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.5. South Korea
7.4.2.5.1. South Korea Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.5.2. South Korea Premenstrual Syndrome Treatment Market, By Type
7.4.2.5.3. South Korea Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.6.2. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Type
7.4.2.6.3. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type
7.4.4. Asia-Pacific Premenstrual Syndrome Treatment Market, By Type
7.4.5. Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5. Lamea
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.1.2. Brazil Premenstrual Syndrome Treatment Market, By Type
7.5.2.1.3. Brazil Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.2.2. Saudi Arabia Premenstrual Syndrome Treatment Market, By Type
7.5.2.2.3. Saudi Arabia Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.3.2. South Africa Premenstrual Syndrome Treatment Market, By Type
7.5.2.3.3. South Africa Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.2.4. Rest of Lamea
7.5.2.4.1. Rest of Lamea Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.4.2. Rest of Lamea Premenstrual Syndrome Treatment Market, By Type
7.5.2.4.3. Rest of Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.3. Lamea Market Size And Forecast, By Drug Type
7.5.4. Lamea Premenstrual Syndrome Treatment Market, By Type
7.5.5. Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel
Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Astrazeneca Plc
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. Basf Corporation
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Bayer Ag.
8.4.1. Company Overview
8.4.2. Operating Business Segments
8.4.3. Product Portfolio
8.4.4. Business Performance
8.5. Dr. ReddyS Laboratories Ltd
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Eli Lilly And Company.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Glaxosmithkline Plc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. H. Lundbeck A/S
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Pfizer Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Shionogi Inc.
8.10.1. Company Overview
8.10.2. Operating Business Segments
8.10.3. Product Portfolio
8.10.4. Business Performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
